Logo image of LXEO

LEXEO THERAPEUTICS INC (LXEO) Stock Fundamental Analysis

NASDAQ:LXEO - Nasdaq - US52886X1072 - Common Stock - Currency: USD

4.76  +0.03 (+0.63%)

After market: 4.76 0 (0%)

Fundamental Rating

1

Taking everything into account, LXEO scores 1 out of 10 in our fundamental rating. LXEO was compared to 551 industry peers in the Biotechnology industry. The financial health of LXEO is average, but there are quite some concerns on its profitability. LXEO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

LXEO had negative earnings in the past year.
LXEO had a negative operating cash flow in the past year.
In the past 5 years LXEO always reported negative net income.
LXEO had a negative operating cash flow in each of the past 5 years.
LXEO Yearly Net Income VS EBIT VS OCF VS FCFLXEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -86.78%, LXEO is doing worse than 72.60% of the companies in the same industry.
LXEO's Return On Equity of -123.78% is in line compared to the rest of the industry. LXEO outperforms 41.20% of its industry peers.
Industry RankSector Rank
ROA -86.78%
ROE -123.78%
ROIC N/A
ROA(3y)-58.41%
ROA(5y)-45.95%
ROE(3y)-74.86%
ROE(5y)-56.75%
ROIC(3y)N/A
ROIC(5y)N/A
LXEO Yearly ROA, ROE, ROICLXEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

LXEO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LXEO Yearly Profit, Operating, Gross MarginsLXEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

4

2. Health

2.1 Basic Checks

Compared to 1 year ago, LXEO has more shares outstanding
The debt/assets ratio for LXEO has been reduced compared to a year ago.
LXEO Yearly Shares OutstandingLXEO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
LXEO Yearly Total Debt VS Total AssetsLXEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

LXEO has an Altman-Z score of -3.33. This is a bad value and indicates that LXEO is not financially healthy and even has some risk of bankruptcy.
LXEO has a Altman-Z score (-3.33) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.01 indicates that LXEO is not too dependend on debt financing.
The Debt to Equity ratio of LXEO (0.01) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -3.33
ROIC/WACCN/A
WACCN/A
LXEO Yearly LT Debt VS Equity VS FCFLXEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 3.42 indicates that LXEO has no problem at all paying its short term obligations.
The Current ratio of LXEO (3.42) is comparable to the rest of the industry.
A Quick Ratio of 3.42 indicates that LXEO has no problem at all paying its short term obligations.
The Quick ratio of LXEO (3.42) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.42
Quick Ratio 3.42
LXEO Yearly Current Assets VS Current LiabilitesLXEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for LXEO have decreased strongly by -22.28% in the last year.
EPS 1Y (TTM)-22.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -1.48% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y12.57%
EPS Next 2Y15.37%
EPS Next 3Y10.18%
EPS Next 5Y-1.48%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
LXEO Yearly Revenue VS EstimatesLXEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
LXEO Yearly EPS VS EstimatesLXEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10 15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

LXEO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year LXEO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
LXEO Price Earnings VS Forward Price EarningsLXEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LXEO Per share dataLXEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.37%
EPS Next 3Y10.18%

More info and screens

0

5. Dividend

5.1 Amount

LXEO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LEXEO THERAPEUTICS INC

NASDAQ:LXEO (8/6/2025, 5:21:05 PM)

After market: 4.76 0 (0%)

4.76

+0.03 (+0.63%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)08-18 2025-08-18/bmo
Inst Owners107.34%
Inst Owner Change0.36%
Ins Owners0.81%
Ins Owner Change-0.28%
Market Cap158.03M
Analysts86.15
Price Target19.38 (307.14%)
Short Float %18.28%
Short Ratio8.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9.32%
Min EPS beat(2)-23.91%
Max EPS beat(2)5.26%
EPS beat(4)2
Avg EPS beat(4)-9.5%
Min EPS beat(4)-28.59%
Max EPS beat(4)9.25%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-10.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)16.24%
EPS NY rev (1m)3.2%
EPS NY rev (3m)14.05%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.79
P/tB 1.79
EV/EBITDA N/A
EPS(TTM)-3.3
EYN/A
EPS(NY)-2.06
Fwd EYN/A
FCF(TTM)-2.66
FCFYN/A
OCF(TTM)-2.65
OCFYN/A
SpS0
BVpS2.65
TBVpS2.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -86.78%
ROE -123.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.41%
ROA(5y)-45.95%
ROE(3y)-74.86%
ROE(5y)-56.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.42
Quick Ratio 3.42
Altman-Z -3.33
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)122.1%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-22.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-28.57%
EPS Next Y12.57%
EPS Next 2Y15.37%
EPS Next 3Y10.18%
EPS Next 5Y-1.48%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-61.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year26.27%
EBIT Next 3Y10.69%
EBIT Next 5YN/A
FCF growth 1Y-50.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-51.89%
OCF growth 3YN/A
OCF growth 5YN/A